# Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation

> **NCT05761717** · NA · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 67 (estimated)

## Conditions studied

- Posto Perative Hepatocellular Carcinoma

## Interventions

- **DRUG:** Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection

## Key facts

- **NCT ID:** NCT05761717
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-20
- **Primary completion:** 2025-03-12
- **Final completion:** 2025-06-12
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05761717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05761717, "Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05761717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*